Kerry (formerly c-LEcta) Verified partner

Its Denarase® endonucleases hydrolyse phosphodiester bonds in all forms of nucleic acid — single- and double-stranded, linear, circular and supercoiled DNA and RNA — down to fragments of roughly 3–5 base pairs. In viral vector and vaccine manufacturing this reduces lysate viscosity, clears host cell DNA, and simplifies the purification steps that follow.

Two variants cover the full process window. The standard Denarase®, referred to by the manufacturer as the wild-type variant, performs best at low to physiological salt (0–150 mM) and remains the more economical option there. Denarase® High Salt is engineered to retain activity from 0 to 500 mM, enabling salt-supplemented lysis conditions that can improve viral vector recovery.

Both variants are produced without animal-derived raw materials, antibiotics or Triton X-100, in a gram-positive Bacillus sp. host that removes the endotoxin risk inherent to gram-negative expression systems. R&D and GMP grades carry identical release specifications, and Kerry maintains a US FDA Drug Master File to support American regulatory submissions.

BioHippo is Kerry's authorized US distributor, supplying the Denarase® portfolio, the companion ELISA kit, and CellTrypase from US-facing stock — R&D grade ships from US inventory in 2–3 business days.